Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Oct 9;9(1):e001790.
doi: 10.1136/bmjophth-2024-001790.

Control of myopia using diffusion optics spectacle lenses: 4-year results of a multicentre randomised controlled, efficacy and safety study (CYPRESS)

Deborah Laughton  1 , Jennifer S Hill  2 , Marcella McParland  2 , Vanessa Tasso  2 , Jill Woods  3 , Xiaoying Zhu  4 , Graeme Young  5 , Ruth Craven  5 , Chris Hunt  5 , Jay Neitz  6 , Maureen Neitz  6 , Thomas W Chalberg  2 , Deborah Jones  3 , James S Wolffsohn  7
Affiliations
Randomized Controlled Trial

Control of myopia using diffusion optics spectacle lenses: 4-year results of a multicentre randomised controlled, efficacy and safety study (CYPRESS)

Deborah Laughton et al. BMJ Open Ophthalmol. .

Abstract

Aims: To evaluate the myopia control efficacy of Diffusion Optics Technology (DOT) spectacle lenses in children over a 4-year treatment period.

Methods: CYPRESS Part 1 (NCT03623074) was a 3-year multicentre, randomised, controlled, double-masked trial comparing two investigational spectacle lens DOT designs (Test 1, Test 2) and standard single vision Control lenses in 256 North American children aged 6-10 years. Children completing Part 1 (n=200) were invited to enrol in CYPRESS Part 2 (NCT04947735) for an additional 1-year period. In Part 2, Test 1 (n=35) and Control groups (n=42) continued with their original lens assignment and the Test 2 group (n=21) were crossed over to Test 1 (DOT 0.2) lenses. The co-primary endpoints were change from baseline in axial length (AL) and cycloplegic spherical equivalent refraction (cSER).

Results: Test 1 spectacle lenses demonstrated superiority to the Control in both co-primary endpoints: with a difference between means (Test 1-Control) of -0.13 mm for AL (p=0.018) and 0.33 D for cSER (p=0.008) in Part 1 and -0.05 mm for AL (p=0.038) and 0.13 D for cSER (p=0.043) in Part 2. Comparing treatment effects in Part 1 and 2 suggests that COVID-19 public health restrictions negatively impacted treatment efficacy in study years 2 and 3.

Conclusion: DOT 0.2 spectacle lenses are safe and effective at reducing myopia progression, with additional benefit evident in year 4 of wear. These results support the hypothesis that a mild reduction in retinal contrast can slow myopia progression in young children. The unprecedented disruption in participant schooling and lifestyle during the COVID-19 pandemic may have depressed treatment efficacy in Part 1.

Keywords: Child health (paediatrics); Clinical Trial.

PubMed Disclaimer

Conflict of interest statement

Competing interests: DL, JSH, MMP and VT are SightGlass Vision employees. VT has a patent application for methods and devices for reducing myopia in children. JW reports research grants from SightGlass Vision, Alcon, CooperVision and Johnson and Johnson Vision and consultancy fees from SightGlass Vision and meeting and/or travel support from Alcon and CopperVision. XZ reports grants from SightGlass Vision and Reality Labs Research at Meta Platforms Technologies, LLC and consultancy fees/honoraria from SightGlass Vision and CooperVision. GY, RC and CH report contracts with SightGlass Vision, Johnson & Johnson Vision, CooperVision and Essilor. JN and MN report royalties/licenses, consulting fees and meeting and/or travel support from SightGlass Vision. JN and MN are cofounders and have stock ownership in SightGlass Vision, and are listed as Inventors on patents issued for DOT lens, owned by the University of Washington. TWC reports consulting fees, meeting and/or travel support, patents and stock ownership in his role as employee, officer and board member for SightGlass Vision. DJ reports consulting/honoraria from CooperVision, Hoya, SightGlass Vision, Alcon and Essilor. JSW reports consulting fees from CooperVision, DopaVision, Essilor, International Myopia Institute, SightGlass Vision and Thea. JSW reports grants from SightGlass Vision and Espansione and shares in Wolffsohn Research Limited.

Figures

Figure 1
Figure 1. Flowchart of participant disposition. T1, Test 1; T2, Test 2.
Figure 2
Figure 2. Least squares mean change from baseline with 95% CI for (A) axial length and (B) cycloplegic spherical equivalent refraction (cSER).
Figure 3
Figure 3. Least squares mean change from baseline with 95% CI for (A) axial length and (B) cycloplegic spherical equivalent refraction (cSER), only including data from the participants who enrolled into Part 2. The Test group includes participants who wore Test 1 or Test 2 lenses for the first 3 years of the study. All participants in the Test group wore Test 1 lenses between study years 3 and 4.
See this image and copyright information in PMC

References

    1. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123:1036–42. doi: 10.1016/j.ophtha.2016.01.006. - DOI - PubMed
    1. McCullough SJ, O’Donoghue L, Saunders KJ. Six Year Refractive Change among White Children and Young Adults: Evidence for Significant Increase in Myopia among White UK Children. PLoS One. 2016;11:e0146332. doi: 10.1371/journal.pone.0146332. - DOI - PMC - PubMed
    1. Flitcroft DI, He M, Jonas JB, et al. IMI – Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies. Invest Ophthalmol Vis Sci. 2019;60:M20. doi: 10.1167/iovs.18-25957. - DOI - PMC - PubMed
    1. Chua SYL, Sabanayagam C, Cheung Y-B, et al. Age of onset of myopia predicts risk of high myopia in later childhood in myopic Singapore children. Ophthalmic Physiol Opt. 2016;36:388–94. doi: 10.1111/opo.12305. - DOI - PubMed
    1. Polling JR, Klaver C, Tideman JW. Myopia progression from wearing first glasses to adult age: the DREAM Study. Br J Ophthalmol. 2022;106:820–4. doi: 10.1136/bjophthalmol-2020-316234. - DOI - PMC - PubMed

Publication types

LinkOut - more resources